SCHEMBL4240240

SCHEMBL4240240

COc1cccc2c(=O)n(NCc3ccc(Cl)cc3)c(-c3ccc(F)cc3)nc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
TNKS O95271 2/20 0.46
TNKS2 Q9H2K2 2/20 0.46
PARP2 Q9UGN5 2/20 0.46
NPSR1 Q6W5P4 3/20 0.46
HPGD P15428 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
CYP1A2 P05177 2/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
LMNA P02545 2/20 0.43
GAA P10253 2/20 0.43
TSHR P16473 1/20 0.43
MAPK1 P28482 1/20 0.43
TRPA1 O75762 1/20 0.43
HTT P42858 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4242256 0.90 MEN1 (0.48) POLBMEN1KMT2ATNKSTNKS2
SCHEMBL4233197 0.89 SMN1; SMN2 (0.48) POLBMEN1KMT2ATNKSTNKS2
SCHEMBL4239826 0.86 SMN1; SMN2 (0.57) POLBMEN1KMT2ATNKSTNKS2
SCHEMBL4237651 0.81 SMN1; SMN2 (0.67) POLBMEN1KMT2ANPSR1HPGD
SCHEMBL4202613 0.80 SMN1; SMN2 (0.48) POLBMEN1KMT2ASMN1; SMN2CYP1A2
SCHEMBL4237523 0.80 CYP3A4 (0.51) POLBMEN1KMT2ANPSR1SMN1; SMN2
SCHEMBL4240578 0.79 POLB (0.64) POLBMEN1KMT2ANPSR1HPGD
SCHEMBL4241365 0.79 SMN1; SMN2 (0.48) POLBMEN1KMT2ATNKSTNKS2
SCHEMBL4233295 0.77 SMN1; SMN2 (0.53) POLBMEN1KMT2ANPSR1SMN1; SMN2
SCHEMBL13930049 0.77 TRPA1 (0.39) POLBMEN1KMT2ATNKSTNKS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-05 US disclosed
WO-2008067219-A2 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2008-06-05 WO disclosed
WO-2008067219-A2 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2008-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 GRK5, PLAAT5, GPBAR1 POLB 4752/4885MEN1 4781/4885KMT2A 4183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.